InMed reports positive INM-901 data in human brain organoid neuroinflammation models

InMed Pharmaceuticals Inc.

INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.
Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.
Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.
Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.